Isuzuma rya Trastuzumab Deruxtecan ryihariye mu Bushinwa ku ndwara ya kanseri y’igifu itera imbere ya HER2

Ku ya 10 Kamena, Ikigo gishinzwe Isuzuma ry’Imiti (CDE) cy’Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cyatangaje ko Trastuzumab Deruxtecan (T-DXd, DS-8201a) iteganijwe guhabwa isuzuma ry’ibanze mu kuvura abarwayi bakuru bafite HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma bavuwe rimwe mbere.

Mu igerageza rya DESTINY-Gastric01 ry’icyiciro cya kabiri, DS-8201 yazamuye cyane igipimo cy’ubutabazi n’ubuzima muri rusange ku barwayi bafite HER2-positive gastric adenocarcinoma (GC) cyangwa gastroesophageal junction (GEJ) adenocarcinoma. Igerageza ryagaragaje abarwayi 125 bavuwe na DS-8201, bagaragaza igipimo cy’ubutabazi (ORR) cya 51%, igipimo cy’ubutabazi (DOR) cy’amezi 11.3, n’igipimo cyo kurwanya indwara (DCR) cya 86%.

Inyigo ya Phase III DESTINY-Gastric04 yasuzumye imikorere n'umutekano wa Trastuzumab Deruxtecan (6.4 mg/kg) ugereranije na ramucirumab hamwe na paclitaxel nk'ubuvuzi bwa kabiri ku barwayi bafite HER2-positive idakira kandi/cyangwa itera metastatic gastric adenocarcinoma cyangwa GEJ adenocarcinoma. Ibisubizo byagaragaje ko, kugeza ku ya 24 Ukwakira 2024, itsinda rya trastuzumab deruxtecan ryagaragaje ko rimaze igihe kirekire cyane ribayeho muri rusange (OS) (amezi 14.7 ugereranyije n'amezi 11.4, HR = 0.70, P = 0.0044) n'ubuzima budafite progression (PFS) (amezi 6.7 ugereranyije n'amezi 5.6). ORR nayo yari hejuru (44.3% ugereranyije na 29.1%), kimwe na DCR (91.9% ugereranyije na 75.9%).

Trastuzumab deruxtecan (yahoze ari DS-8201), ikoreshwa ry’umuti urwanya indwara ugizwe n’umuti urwanya HER2 monoclonal uhujwe n’umuti ugabanya ubukana bwa topoisomerase I ukoresheje tetrapeptide-based cleavable linker, yemejwe kuvura abarwayi ba kanseri y’ibere ya HER2-positive. Bitandukanye n’ubundi buryo bwinshi bwemewe bwo kuvura bugamije HER2, trastuzumab deruxtecan ishobora kandi kwibasira uturemangingo tw’uturemangingo tw’uturemangingo tugaragaza urugero ruto rwa HER2 kandi ishobora gutanga umutwaro wayo ukomeye wa cytotoxic payload (ikigereranyo cy’umuti-ku-antibody, 8:1) binyuze mu ngaruka z’uturemangingo tw’uturemangingo tw’uturemangingo tw’uturemangingo tuyikikije tugaragaza HER2 mu buryo butandukanye.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com